Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Generic Formulation Products

Download Brochure
Therapy Area Product Name Oral Inj Strength Dossier Status Connect
Oncology Azacitidine 100 mg Filed
Oncology Bendamustine 25, 100mg Filed
Oncology Bendamustine RTU 180 mg/ 4 ml, 100 mg/ 4 ml Filed
Oncology Bortezomib 3.5 mg Filed
Oncology Cabazitaxel 60 mg/ 1.5 ml Filed
Oncology Carfilzomib 30 mg/ml, 60 mg/ml Filed
Oncology Decitabine 50 mg Filed
Oncology Eribulin 1 mg/2 ml Under Development
Oncology Fulvestrant 50 mg/ml Filed
Oncology Fosaprepitant 150 mg/ ml Filed
Oncology Liposomal Doxorubicin 20 mg/10 ml ,50 mg/25 ml Filed
Oncology Palonosetron 0.075 mg/5 ml, 0.25 mg/ 5 ml Filed
Oncology Pemetrexed 100 mg, 500 mg, 1000 mg Filed
Oncology Plerixafor 24 mg/1.2 ml Filed
Oncology Zoledronic Acid 4 mg/5 ml, 5 mg/100 ml, 4 mg/100 ml Filed
Oncology Abiraterone 250 mg Filed
Oncology Abiraterone 500 mg Under Development
Oncology Capecitabine 150 mg, 500 mg Filed
Oncology Dasatinib 20, 50, 70, 80,100 and 140 mg Filed
Oncology Enzalutamide 40 mg Under Development
Oncology Everolimus 2.5, 5, 7.5, 10 mg Under Development
Oncology Lenalidomide 2.5, 5, 10, 15, 20, 25 mg Filed
Oncology Lenvatinib 4, 10 mg Under Development
Oncology Nilotinib 150, 200 mg Under Development
Oncology Palbociclib 75, 100, 125 mg Filed
Oncology Pomalidomide 1,2,3,4 mg Filed
Oncology Imatinib Mesylate 100 MG AND 400 MG Filed
Oncology Carmustine 100 mg/vial Filed
Oncology Venetoclax 10 mg, 50 mg and 100 mg Filed
Oncology Sorafenib 200 mg Filed
Oncology Midostaurin 25 mg Filed
Oncology Sunitinib Malate 12.5 mg, 25 mg, 37.5 mg and 50 mg Filed
Oncology Nano Paclitaxel 100mg Under Development
Oncology Axitinib 1mg, 3mg, 5mg, 7mg Under Development
Oncology Cabozantinib 20 mg, 40 mg and 60 mg Under Development
Oncology Sunitinib 12.5Mg;25Mg;37.5Mg;50Mg Filed
Oncology Tofacitinib XR Tofacitinib XR Under Development
Oncology Pazopanib 200 and 400 mg Under Development
Oncology Nintedanib 100 mg & 150 mg Under Development
Oncology / Acromegaly Octerotide 10mg, 20mg & 30mg Under Development
Oncology / Acromegaly Lanreotide 60mg/0.2mL, 90mg/0.3mL and 120mg/0.5mL Under Development
Central Nervous System Glatiramer 20, 40 mg Filed
Central Nervous System Sugammadex 100 mg/ml Filed
Central Nervous System Pregabalin 25, 50, 75, 100, 150, 200, 225, 300 mg Filed
Oncology Fingolimod 0.5 mg Filed
Cardiovascular Fondaparinux 2.5, 5, 7.5, 10mg Filed
Oncology Dimethyl Fumarate 120mg, 240mg Under Development
Cardiovascular Treprostinil 1, 2.5, 5, 10mg/ml Filed
Cardiovascular Apixaban 2.5, 5mg Filed
Cardiovascular Dabigatran 75 , 110, 150 mg Filed
Cardiovascular Rivaroxaban 10, 15, 20 mg Filed
Cardiovascular Sacubitril/ Valsartan 24/26, 49/51, 97/103 mg Filed
Cardiovascular Ticagrelor 60, 90 mg Filed
Cardiovascular Icosapent Ethy 1 g Filed
Anti-Diabetic Canagliflozin + Metformin
*This product is not available for commercial use. It would be available only for Section 107A purposes.
 150 mg/1000 mg, 150 mg/500 mg, 50mg/1000 mg, 50 mg/500 mg Filed
Anti-Diabetic Linagliptin 5 mg Filed
Anti-Diabetic Linagliptin + Metformin 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg Filed
Anti-Diabetic Liraglutide 6mg/ml – 3 ml fill pen Under Development
Anti-Diabetic Semaglutide 2mg/1.5mL; 4mg/3mL Under Development
Anti-Obesity Liraglutide 6mg/ml – 3 ml fill pen Under Development
Gastro-Intestinal Esomeprazole 20, 40mg Filed
Gastro-Intestinal Esomeprazole MG + Naproxen Na 20 mg/375 mg, 20 mg/500 mg Filed
Gastro-Intestinal Lansoprazole ODT 15 mg and 30 mg Filed
Immuno Suppressant Sirolimus 1 mg and 2 mg Filed
Immuno Suppressant Tacrolimus 0.5 mg, 1 mg and 5 mg Filed
Others Daptomycin 350, 500 mg Filed
Others Icatibant 30 mg base /3 ml PFS Filed
Others Iron Sucrose 100 mg/5 ml, 200 mg/10 ml, 50 mg/2.5 ml Filed
Others 阿普斯特 10, 20, 30 mg Filed
Others Sevelamer Carbonate 800 mg Filed
Others Valganciclovir 450 mg Filed
Others Isotretinoin 10mg, 20mg, 30mg and 40mg Filed
Others Varenicline 0.5 mg and 1 mg Filed
Others Teriparatide 0.6 mg/2.4 mL (0.25 mg/mL) Under Development
Others Rifaximine 550mg Under Development
Others Amphotericin B 50mg Under Development
Others Mesalamine 250 and 500 mg Under Development
Generic Formulation

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

X
Connect & collaborate with us at

 

Meet us in BOOTH 4C30

24th-26th October 2023    Fira Barcelona Gran Via, Spain

Sign up